Cellectis Inc.

Good morning, everyone, and welcome to the Selectus first quarter 2020 results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. Please be aware that today's conference call is being recorded. I'd now like to introduce the first speaker, Simon Harness, Selectus Vice President of Corporate Strategy and Finance. You may begin.

Thank you and welcome everyone to Selected's first quarter 2020 Corporate Update and Financial Results Conference Call. Joining me on the call today with prepared remarks are Dr. Andre Choulika, our Chairman and Chief Executive Officer, Dr. Carrie Brownstein, Chief Medical Officer, Bill Montes, Executive Vice President, Technical Operations, and Eric Dutton, our Chief Financial Officer. Yesterday evening, Selectis issued a press release reporting our financial results for the first quarter ended March 31, 2020. The press release is available on our website at selectis.com. As a reminder, we will make forward-looking statements regarding financial outlook in addition to regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20F, on file with the SEC and in the financial report, including the management report for the year ended December 31st, 2019, and subsequent filing selectors make with the Securities Exchange Commission from time to time. I would now like to turn the call over to Andre. Andre, please go ahead.

Thank you, Simon. Good morning and thank you everyone for joining us today. Before we begin with our corporate update for the first quarter 2020, I would like to extend my heartfelt gratitude to everyone on the phone for your continued support of the entire healthcare space during these exceptional times. I would especially like to extend my highest appreciation to all healthcare workers from the doctors to nurses who never gave up and are battling cancer and on the frontline to our colleagues in the biotech industry and academic institutions who are working day and night on a cure for all cancer patients. We at Selectis keep our focus and never gave up an inch during these times. I'm proud to say that we are carrying a strong momentum from the start of 2020 through these recent weeks. as all three of our proprietary allogenic CAR T-cell product candidates are progressing in clinical development and continuing to recruit patients. This would not be possible without the commitment and passion from each of our principal investigators, our clinical partners, as well as our team at Selectus. In parallel to our clinical progress, We have not stopped our R&D operations in New York and in Paris, as well as the construction of our in-house manufacturing sites in Raleigh and Paris. It is now my great pleasure to introduce my esteemed colleague, Dr. Carrie Brownstein, our newly appointed Chief Medical Officer. Carrie brings to Selectus her strong industry expertise and an impressive track record in clinical development across all phases of the product life cycle, including successful regulatory filing in the US and the EU for novel products. Dr. Brownstein joined us from Celgene, where she served as Vice President, Global Clinical Research and Development, therapeutic area head of myelid diseases. Prior to Celgene, Dr. Brownstein served as Executive Director, Clinical Science Oncology at Regeneron, where she led the team of investigating multiple early development program and assets, including T-cell engaging by specific antibodies. Dr. Brownstein started her industry career at Roche as Senior Medical Director supporting the development and approval of a number of hematology and oncology therapies. Prior to her industry career, Carrie practiced medicine as a pediatric oncologist at the New York Presbyterian at Columbia University and Mount Sinai Medical Center. I would now like to hand the call over to Carrie for an overview of our clinical programs, then Bill will review every manufacturing update and Eric will give an update on financials. Kerry, please go ahead.